Drug intelligence / Profile preview

OPC-64005

Development stage: Phase 2
Lead developer: Otsuka Holdings
Modality: Small Molecules
Administration: Oral

Overview

OPC-64005 is an investigational small molecule drug classified as a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), also known as a "triple reuptake inhibitor" (TRI). It acts by inhibiting the reuptake of serotonin, norepinephrine (adrenergic), and dopamine, thereby increasing the levels of these neurotransmitters in the brain. The drug is being developed primarily for the treatment of major depressive disorder and was previously investigated for attention deficit hyperactivity disorder (ADHD), though development for ADHD has been discontinued. OPC-64005 is administered orally. The developer and manufacturer is Otsuka Pharmaceutical[1][2][4].

Targets

SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)

Beyond the preview

Go deeper on OPC-64005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OPC-64005.

Explore the full profile